// App-Quantinova.ai

4740 : Targeting Ref-1/APE1 pathway inhibition in pancreatic cancer using APX3330 for clinical trials

Researchers

Presenter

  • Melissa L. Fishel

Principal Investigators

  • Derek P. Logsdon

  • Michelle L. Grimard

  • Claudiu T. Supuran

  • Nicholas Zyromski

  • Mircea Ivan

  • Mark R. Kelley

  • Fenil Shah

Medical Centers

  • Indiana University School of Medicine, Indianapolis, IN

  • University of Florence, Florence, Italy

Locations

  • United States

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Pancreas ductal adenocarcinoma

  • Pancreatic cancer

  • Solid malignancies

  • Microphthalmia, syndromic, 9

Biomarkers

  • Apurinic/Apyrimidinic Endodeoxyribonuclease 1

Drug/Treatment

  • Gemcitabine

  • Oxaliplatin

  • Irinotecan

  • leucovorin

  • Paclitaxel

  • FOLFIRINOX

  • E-3330

  • Adrucil injection

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved